196 related articles for article (PubMed ID: 35042096)
1. Examining a brief measure and observed cutoff scores to identify reward and relief drinking profiles: Psychometric properties and pharmacotherapy response.
Votaw VR; Mann K; Kranzler HR; Roos CR; Nakovics H; Witkiewitz K
Drug Alcohol Depend; 2022 Mar; 232():109257. PubMed ID: 35042096
[TBL] [Abstract][Full Text] [Related]
2. Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response Among Reward and Relief Drinking Phenotypes.
Mann K; Roos CR; Hoffmann S; Nakovics H; Leménager T; Heinz A; Witkiewitz K
Neuropsychopharmacology; 2018 Mar; 43(4):891-899. PubMed ID: 29154368
[TBL] [Abstract][Full Text] [Related]
3. Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.
Roos CR; Mann K; Witkiewitz K
Addict Biol; 2017 Nov; 22(6):1528-1539. PubMed ID: 27480445
[TBL] [Abstract][Full Text] [Related]
4. Advancing Precision Medicine for Alcohol Use Disorder: Replication and Extension of Reward Drinking as a Predictor of Naltrexone Response.
Witkiewitz K; Roos CR; Mann K; Kranzler HR
Alcohol Clin Exp Res; 2019 Nov; 43(11):2395-2405. PubMed ID: 31436886
[TBL] [Abstract][Full Text] [Related]
5. Baclofen for alcohol use disorder.
Agabio R; Saulle R; Rösner S; Minozzi S
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012557. PubMed ID: 36637087
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis.
Donoghue K; Elzerbi C; Saunders R; Whittington C; Pilling S; Drummond C
Addiction; 2015 Jun; 110(6):920-30. PubMed ID: 25664494
[TBL] [Abstract][Full Text] [Related]
7. Comparing the psychometric properties of reward and relief drinking measures.
Votaw VR; Pearson MR; Kranzler HR; Roos CR; Yeater EA; Witkiewitz K
Exp Clin Psychopharmacol; 2024 Jun; ():. PubMed ID: 38900509
[TBL] [Abstract][Full Text] [Related]
8. Reward drinking and naltrexone treatment response among young adult heavy drinkers.
Roos CR; Bold KW; Witkiewitz K; Leeman RF; DeMartini KS; Fucito LM; Corbin WR; Mann K; Kranzler HR; O'Malley SS
Addiction; 2021 Sep; 116(9):2360-2371. PubMed ID: 33620746
[TBL] [Abstract][Full Text] [Related]
9. Baclofen for alcohol use disorder.
Minozzi S; Saulle R; Rösner S
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012557. PubMed ID: 30484285
[TBL] [Abstract][Full Text] [Related]
10. Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials.
Falk D; Wang XQ; Liu L; Fertig J; Mattson M; Ryan M; Johnson B; Stout R; Litten RZ
Alcohol Clin Exp Res; 2010 Dec; 34(12):2022-34. PubMed ID: 20659066
[TBL] [Abstract][Full Text] [Related]
11. SAEM GRACE: Anti-craving medications for alcohol use disorder treatment in the emergency department: A systematic review of direct evidence.
Punia K; Scott W; Manuja K; Sabbineni M; Campbell K; Balodis IM; MacKillop J
Acad Emerg Med; 2024 May; 31(5):504-514. PubMed ID: 37735346
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review.
Kranzler HR; Soyka M
JAMA; 2018 Aug; 320(8):815-824. PubMed ID: 30167705
[TBL] [Abstract][Full Text] [Related]
13. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study.
Greenfield SF; Pettinati HM; O'Malley S; Randall PK; Randall CL
Alcohol Clin Exp Res; 2010 Oct; 34(10):1803-12. PubMed ID: 20645934
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.
Falk DE; O'Malley SS; Witkiewitz K; Anton RF; Litten RZ; Slater M; Kranzler HR; Mann KF; Hasin DS; Johnson B; Meulien D; Ryan M; Fertig J;
JAMA Psychiatry; 2019 Apr; 76(4):374-381. PubMed ID: 30865232
[TBL] [Abstract][Full Text] [Related]
15. Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study.
Mann K; Kiefer F; Smolka M; Gann H; Wellek S; Heinz A;
Alcohol Clin Exp Res; 2009 Apr; 33(4):674-83. PubMed ID: 19170666
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.
Kranzler HR; Van Kirk J
Alcohol Clin Exp Res; 2001 Sep; 25(9):1335-41. PubMed ID: 11584154
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
Palpacuer C; Duprez R; Huneau A; Locher C; Boussageon R; Laviolle B; Naudet F
Addiction; 2018 Feb; 113(2):220-237. PubMed ID: 28940866
[TBL] [Abstract][Full Text] [Related]
18. Impact of policy changes and drug shortages on acamprosate and naltrexone use in Ontario, Canada.
Konstantelos N; Tourchian N; McCormack D; Lecce P; Tadrous M; Gomes T
Drug Alcohol Depend; 2023 Jan; 242():109705. PubMed ID: 36463765
[TBL] [Abstract][Full Text] [Related]
19. Examining the validity of the drinking motives questionnaire for identifying reward and relief drinking subgroups in college students.
Hebden HM; Votaw VR; Herchenroeder L; Witkiewitz K; Yeung EW
Alcohol Clin Exp Res (Hoboken); 2023 Nov; 47(11):2184-2196. PubMed ID: 38226750
[TBL] [Abstract][Full Text] [Related]
20. Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125 556 patients.
Heikkinen M; Taipale H; Tanskanen A; Mittendorfer-Rutz E; Lähteenvuo M; Tiihonen J
Addiction; 2021 Aug; 116(8):1990-1998. PubMed ID: 33394527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
